Doravirine vs Emtricitabine/tenofovir disoproxil fumarate

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV reverse transcriptase · full HIV pipeline

Doravirine · Pifeltro

Marketed by Merck & Co.

Approved in HIVsmall molecule
Reliable signal

NCT02275780 · Phase 3 · completed

This was a randomized, double-blind, active-controlled Phase 3 trial with 769 enrolled adults (385 doravirine, 384 darunavir/ritonavir). The primary endpoint was virologic suppression (HIV-1 RNA <50 copies/mL) at Week 48, a hard clinical endpoint. The non-inferiority comparison was met: the difference was 3.9 percentage points (95% CI -1.6 to 9.4), with the lower bound above the prespecified -10% margin. The trial therefore provides strong evidence that doravirine is non-inferior to darunavir/ritonavir.

Next expected readout: November 2026 · NCT04892654 (registry estimate)

Reported efficacy

Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48; Percentage of Participants With Tier-1 Neuropsychiatric Adverse Events (AEs) (Up to Week 48): Week 48 HIV-1 RNA <50 copies/mL: 84.3% doravirine/tenofovir/lamivudine vs 80.8% ATRIPLA; treatment difference 3.537 percentage points (95% CI -1.951 to 9.026), with a non-inferiority margin of -10. Tier-1 neuropsychiatric events: dizziness 8.8% vs 37.1% (difference -28.3, p<0.001); sleep disorders/disturbances 12.1% vs 25.5% (difference -13.5, p<0.001); altered sensorium 4.4% vs 8.2% (difference -3.8, p=0.033). (met)

Result source: NCT02403674

Emtricitabine/tenofovir disoproxil fumarate · Truvada

Marketed by Gilead Sciences

Approved in HIVsmall molecule combination
Partial signal

NCT00323544 · Phase 3 · completed

This was a randomized, open-label, active-controlled trial of 220 participants, comparing Truvada with Combivir. Its primary endpoint was a laboratory measure—change in hemoglobin—not a hard clinical or endoscopic outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: December 2026 · NCT07584122 (registry estimate)

Reported efficacy

The primary endpoint for the study is a change from baseline in absolute haemoglobin at Week 24.: Primary endpoint, week 24 change from baseline in absolute hemoglobin: switching to Truvada+efavirenz vs continuing Combivir+efavirenz, mean difference +0.37 g/dL (95% CI 0.15 to 0.58 g/dL), P<0.001, favoring the switch arm. (met)

Result source: NCT00323544

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDoravirineEmtricitabine/​tenofovir disoproxil fumarate
HIV-1 RNA below 50 copies/mL (week 48)83.8% vs 79.9%vs Daurunavir + Ritonavir100 mg · wk 48 · n 383NCT02275780
3 other results
  • 84.3% vs 80.8% wk 48 · n 364 · Phase 3 · primary NCT02403674
  • 73.1% vs 66% 100 mg · wk 96 · n 379 · Phase 3 · secondary NCT02275780
  • 77.5% vs 73.6% wk 96 · n 364 · Phase 3 · secondary NCT02403674
83.8% vs 79.9%vs Daurunavir + Ritonavir100 mg · wk 48 · n 383NCT02275780
5 other results
  • 85.2% vs 87.4% wk 48 · n 344 · Phase 3 · primary NCT01108510
  • 73.1% vs 66% 100 mg · wk 96 · n 379 · Phase 3 · secondary NCT02275780
  • 77.9% vs 79.3% wk 96 · n 344 · Phase 3 · secondary NCT01108510
  • 72.1% vs 74.1% wk 144 · n 344 · Phase 3 · secondary NCT01108510
  • 71.6% vs 79.7% wk 192 · n 74 · Phase 3 · secondary NCT01108510
HIV-1 RNA 50 copies/mL or more (week 48)0% vs 1.5%vs Baseline Antiretroviral Therapy (ART)wk 48 · n 336NCT04223778—Not posted · NCT00323544
CD4 count, change (week 48)224.1 vs 206.7vs Daurunavir + Ritonavir100 mg · wk 96 · n 342NCT02275780
14 other results
  • 192.7 vs 185.6 100 mg · wk 48 · n 363 · Phase 3 · secondary NCT02275780
  • 217.1 vs 319.9 100 mg/0.75 mg · wk 96 · n 159 · Phase 3 · secondary NCT04233879
  • 182.4 vs 233.5 100 mg/0.75 mg · wk 48 · n 263 · Phase 3 · secondary NCT04233879
  • 0.5 vs 66.3 wk 144 · n 170 · Phase 3 · secondary NCT04223791
  • 5.4 vs 62.7 wk 96 · n 273 · Phase 3 · secondary NCT04223791
  • -19.7 vs 40.5 wk 48 · n 301 · Phase 3 · secondary NCT04223791
  • 239.6 vs 350.9 100 mg/0.75 mg · wk 144 · n 24 · Phase 3 · secondary NCT04233879
  • 259.2 vs 263.6 100 mg · wk 96 · n 95 · Phase 2 · secondary NCT01632345
  • 191.9 vs 194.5 100 mg · wk 48 · n 102 · Phase 2 · secondary NCT01632345
  • 133.6 vs 121.1 100 mg · wk 24 · n 41 · Phase 2 · secondary NCT01632345
  • 152.3 vs 146 100 mg · wk 24 · n 106 · Phase 2 · secondary NCT01632345
  • 140.7 vs 121.1 200 mg · wk 24 · n 40 · Phase 2 · secondary NCT01632345
  • 112.9 vs 121.1 50 mg · wk 24 · n 41 · Phase 2 · secondary NCT01632345
  • 154.1 vs 121.1 25 mg · wk 24 · n 38 · Phase 2 · secondary NCT01632345
224.1 vs 206.7vs Daurunavir + Ritonavir100 mg · wk 96 · n 342NCT02275780
12 other results
  • 192.7 vs 185.6 100 mg · wk 48 · n 363 · Phase 3 · secondary NCT02275780
  • 310 vs 332 wk 144 · n 275 · Phase 3 · secondary NCT01108510
  • 277 vs 287 wk 96 · n 300 · Phase 3 · secondary NCT01108510
  • 291 vs 256 wk 96 · n 121 · Phase 3 · secondary NCT00089505
  • 223 vs 256 wk 96 · n 249 · Phase 3 · secondary NCT00089505
  • 213 vs 219 wk 48 · n 313 · Phase 3 · secondary NCT01108510
  • 172 vs 172 wk 48 · n 249 · Phase 3 · secondary NCT00089505
  • 350 vs 343 wk 192 · n 73 · Phase 3 · secondary NCT01108510
  • 191 vs 172 wk 48 · n 121 · Phase 3 · secondary NCT00089505
  • 158 vs 146 wk 48 · n 424 · Phase 4 · secondary NCT01380080
  • 96 vs 102 wk 24 · n 424 · Phase 4 · secondary NCT01380080
  • 8 vs 34 wk 48 · n 135 · Phase 4 · secondary NCT00724711

HIV-1 RNA below 50 copies/mL (week 48)

Doravirine
83.8% vs 79.9%vs Daurunavir + Ritonavir100 mg · wk 48 · n 383NCT02275780
3 other results
  • 84.3% vs 80.8% wk 48 · n 364 · Phase 3 · primary NCT02403674
  • 73.1% vs 66% 100 mg · wk 96 · n 379 · Phase 3 · secondary NCT02275780
  • 77.5% vs 73.6% wk 96 · n 364 · Phase 3 · secondary NCT02403674
Emtricitabine/​tenofovir disoproxil fumarate
83.8% vs 79.9%vs Daurunavir + Ritonavir100 mg · wk 48 · n 383NCT02275780
5 other results
  • 85.2% vs 87.4% wk 48 · n 344 · Phase 3 · primary NCT01108510
  • 73.1% vs 66% 100 mg · wk 96 · n 379 · Phase 3 · secondary NCT02275780
  • 77.9% vs 79.3% wk 96 · n 344 · Phase 3 · secondary NCT01108510
  • 72.1% vs 74.1% wk 144 · n 344 · Phase 3 · secondary NCT01108510
  • 71.6% vs 79.7% wk 192 · n 74 · Phase 3 · secondary NCT01108510

HIV-1 RNA 50 copies/mL or more (week 48)

Doravirine
0% vs 1.5%vs Baseline Antiretroviral Therapy (ART)wk 48 · n 336NCT04223778
Emtricitabine/​tenofovir disoproxil fumarate
—Not posted · NCT00323544

CD4 count, change (week 48)

Doravirine
224.1 vs 206.7vs Daurunavir + Ritonavir100 mg · wk 96 · n 342NCT02275780
14 other results
  • 192.7 vs 185.6 100 mg · wk 48 · n 363 · Phase 3 · secondary NCT02275780
  • 217.1 vs 319.9 100 mg/0.75 mg · wk 96 · n 159 · Phase 3 · secondary NCT04233879
  • 182.4 vs 233.5 100 mg/0.75 mg · wk 48 · n 263 · Phase 3 · secondary NCT04233879
  • 0.5 vs 66.3 wk 144 · n 170 · Phase 3 · secondary NCT04223791
  • 5.4 vs 62.7 wk 96 · n 273 · Phase 3 · secondary NCT04223791
  • -19.7 vs 40.5 wk 48 · n 301 · Phase 3 · secondary NCT04223791
  • 239.6 vs 350.9 100 mg/0.75 mg · wk 144 · n 24 · Phase 3 · secondary NCT04233879
  • 259.2 vs 263.6 100 mg · wk 96 · n 95 · Phase 2 · secondary NCT01632345
  • 191.9 vs 194.5 100 mg · wk 48 · n 102 · Phase 2 · secondary NCT01632345
  • 133.6 vs 121.1 100 mg · wk 24 · n 41 · Phase 2 · secondary NCT01632345
  • 152.3 vs 146 100 mg · wk 24 · n 106 · Phase 2 · secondary NCT01632345
  • 140.7 vs 121.1 200 mg · wk 24 · n 40 · Phase 2 · secondary NCT01632345
  • 112.9 vs 121.1 50 mg · wk 24 · n 41 · Phase 2 · secondary NCT01632345
  • 154.1 vs 121.1 25 mg · wk 24 · n 38 · Phase 2 · secondary NCT01632345
Emtricitabine/​tenofovir disoproxil fumarate
224.1 vs 206.7vs Daurunavir + Ritonavir100 mg · wk 96 · n 342NCT02275780
12 other results
  • 192.7 vs 185.6 100 mg · wk 48 · n 363 · Phase 3 · secondary NCT02275780
  • 310 vs 332 wk 144 · n 275 · Phase 3 · secondary NCT01108510
  • 277 vs 287 wk 96 · n 300 · Phase 3 · secondary NCT01108510
  • 291 vs 256 wk 96 · n 121 · Phase 3 · secondary NCT00089505
  • 223 vs 256 wk 96 · n 249 · Phase 3 · secondary NCT00089505
  • 213 vs 219 wk 48 · n 313 · Phase 3 · secondary NCT01108510
  • 172 vs 172 wk 48 · n 249 · Phase 3 · secondary NCT00089505
  • 350 vs 343 wk 192 · n 73 · Phase 3 · secondary NCT01108510
  • 191 vs 172 wk 48 · n 121 · Phase 3 · secondary NCT00089505
  • 158 vs 146 wk 48 · n 424 · Phase 4 · secondary NCT01380080
  • 96 vs 102 wk 24 · n 424 · Phase 4 · secondary NCT01380080
  • 8 vs 34 wk 48 · n 135 · Phase 4 · secondary NCT00724711
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety

Coverage. Doravirine: 11 of 11 rows · Emtricitabine/tenofovir disoproxil fumarate: 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDoravirine
Rows use multiple source trials
Emtricitabine/​tenofovir disoproxil fumarate
Rows use multiple source trials
HDL-C Change mg/dL
absolute change · mg/dL
Maintenance
Change from Baseline
3.94 vs 4.15 Daurunavir + Ritonavir mg/dL @ 48wk100 mga,b
Change from Baseline
NCT02275780 · Phase 3 · combination
3.94 vs 4.15 Daurunavir + Ritonavir mg/dL @ 48wk100 mga,b
Change from Baseline
NCT02275780 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 40 Copies
responder rate · % of participants
Maintenance
72% (n=379) vs 64.4% (n=376) Daurunavir + Ritonavir @ 96wk100 mga,b
NCT02275780 · Phase 3 · combination
1 other source trial
76.1% (n=364) vs 72.8% (n=364) ATRIPLA @ 96wk
NCT02403674 · Phase 3 · HIV · phase 3
72% (n=379) vs 64.4% (n=376) Daurunavir + Ritonavir @ 96wk100 mga,b
NCT02275780 · Phase 3 · registry result, not featured evidence
HIV-1 RNA LT 200 Copies
responder rate · % of participants
Maintenance
89.6% (n=298) vs 88.6% (n=299) BIC/FTC/TAF @ 48wk100 mg/0.75 mgc,a
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
1 other source trial
85.2% (n=108) vs 85% (n=107) Efavirenz @ 48wk100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
86.4% (n=154) vs 83.3% (n=156) ABC/3TC @ 48wkd,c,a
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
99.2% (n=154) vs 97.2% (n=156) ABC/3TC @ 48wk
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
LDL-C
absolute change · mg/dL
Maintenance
Change from Baseline
-4.51 vs 9.92 Daurunavir + Ritonavir mg/dL @ 48wk100 mga,b
Change from Baseline
NCT02275780 · Phase 3 · combination
-4.51 vs 9.92 Daurunavir + Ritonavir mg/dL @ 48wk100 mga,b
Change from Baseline
NCT02275780 · Phase 3 · registry result, not featured evidence
Non-HDL-C Change mg/dL
absolute change · mg/dL
Maintenance
Change from Baseline
-5.3 vs 13.75 Daurunavir + Ritonavir mg/dL @ 48wk100 mga,b
Change from Baseline
NCT02275780 · Phase 3 · combination
-5.3 vs 13.75 Daurunavir + Ritonavir mg/dL @ 48wk100 mga,b
Change from Baseline
NCT02275780 · Phase 3 · registry result, not featured evidence
Total Cholesterol Change mg/dL
absolute change · mg/dL
No placebo or comparator arm
Change from Baseline
-1.37 mg/dL @ 48wk100 mga,b
Change from Baseline
NCT02275780 · Phase 3 · combination
-1.37 mg/dL @ 48wk100 mga,b
Change from Baseline
NCT02275780 · Phase 3 · registry result, not featured evidence
Triglyceride Change mg/dL
absolute change · mg/dL
Maintenance
Change from Baseline
-3.14 vs 21.97 Daurunavir + Ritonavir mg/dL @ 48wk100 mga,b
Change from Baseline
NCT02275780 · Phase 3 · combination
-3.14 vs 21.97 Daurunavir + Ritonavir mg/dL @ 48wk100 mga,b
Change from Baseline
NCT02275780 · Phase 3 · registry result, not featured evidence
Dropout rate
24.2%100 mge
NCT02275780 · Phase 3 · combination
show 44 more results
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (From Day 1) at B
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch at Week 96 Base
NCT02403674 · Phase 3 · HIV · phase 3
19.6%MK-1439A (DOR/3TC/TDF From Day 1)
NCT02403674 · Phase 3 · HIV · phase 3
10%Cohort 1: DOR
NCT03332095 · Phase 1/2
2.2%Cohort 2: DOR/3TC/TDF
NCT03332095 · Phase 1/2 · combination
20.4%100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
8.2%100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
0%
NCT04689737 · Phase 4 · registry result, not featured evidence
30.4%DOR/ISL
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 0 - Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 48-Week 9
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 96-Week 1
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Open-Label Extension Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Post-Treatment Follow-Up
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
80.2%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—Group 1: DOR/ISL Weeks 0-48
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 1: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
17%Group 1: Doravirine/Islatravir (DO
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 2: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
42.9%DOR/ISL + ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
—DOR/ISL+ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
33.3%DOR/ISL: Treatment Naive Cohort
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Treatment Naive Cohort Ex
NCT04295772 · Phase 2 · registry result, not featured evidence
43.6%DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—50 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
28.6%
NCT04900974 · Phase 1 · registry result, not featured evidence
0%
NCT02715700 · Phase 1 · registry result, not featured evidence · combination
0%200 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
24.7%f
NCT00458393 · Phase 3
show 15 more results
16%Rectal Gel Lubricant + Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence · combination
24%Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence
20%
NCT01380080 · Phase 4 · registry result, not featured evidence
—
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
0%200/300 mg, Daily, by Mouth
NCT00960622 · Phase 4 · registry result, not featured evidence
—Truvada
NCT00960622 · Phase 4 · registry result, not featured evidence
—
NCT00323492 · Phase 4 · registry result, not featured evidence
24.2%100 mg
NCT02275780 · Phase 3 · registry result, not featured evidence
—1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
79.9%
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
25%
NCT01195467 · Phase 3 · registry result, not featured evidence
19.5%
NCT00625404 · Phase 3 · registry result, not featured evidence
25.5%400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence
7.4%NVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
8.4%NoNVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
1.6%100 mge
NCT02275780 · Phase 3 · combination
show 44 more results
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (From Day 1) at B
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch at Week 96 Base
NCT02403674 · Phase 3 · HIV · phase 3
3%MK-1439A (DOR/3TC/TDF From Day 1)
NCT02403674 · Phase 3 · HIV · phase 3
—Cohort 1: DOR
NCT03332095 · Phase 1/2
—Cohort 2: DOR/3TC/TDF
NCT03332095 · Phase 1/2 · combination
—100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
—100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
—
NCT04689737 · Phase 4 · registry result, not featured evidence
—DOR/ISL
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 0 - Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 48-Week 9
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 96-Week 1
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Open-Label Extension Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Post-Treatment Follow-Up
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—Group 1: DOR/ISL Weeks 0-48
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 1: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 1: Doravirine/Islatravir (DO
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 2: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
—DOR/ISL + ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
—DOR/ISL+ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
—DOR/ISL: Treatment Naive Cohort
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Treatment Naive Cohort Ex
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—50 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—
NCT04900974 · Phase 1 · registry result, not featured evidence
—
NCT02715700 · Phase 1 · registry result, not featured evidence · combination
—200 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
—25 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
—f
NCT00458393 · Phase 3
show 15 more results
0%Rectal Gel Lubricant + Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence · combination
8%Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence
—
NCT01380080 · Phase 4 · registry result, not featured evidence
—
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
—200/300 mg, Daily, by Mouth
NCT00960622 · Phase 4 · registry result, not featured evidence
—Truvada
NCT00960622 · Phase 4 · registry result, not featured evidence
—
NCT00323492 · Phase 4 · registry result, not featured evidence
1.6%100 mg
NCT02275780 · Phase 3 · registry result, not featured evidence
—1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
7.4%
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
—
NCT01195467 · Phase 3 · registry result, not featured evidence
—
NCT00625404 · Phase 3 · registry result, not featured evidence
5%400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence
—NVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
—NoNVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
Serious AEs
11.7%100 mge
NCT02275780 · Phase 3 · combination
show 44 more results
6.5%DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
4.2%DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
1.7%DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
6%DOR/3TC/TDF Only (From Day 1) at B
NCT02403674 · Phase 3 · HIV · phase 3
4.5%DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
5.2%DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
6.3%DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
8.2%DOR/3TC/TDF Switch at Week 96 Base
NCT02403674 · Phase 3 · HIV · phase 3
—MK-1439A (DOR/3TC/TDF From Day 1)
NCT02403674 · Phase 3 · HIV · phase 3
0%Cohort 1: DOR
NCT03332095 · Phase 1/2
4.4%Cohort 2: DOR/3TC/TDF
NCT03332095 · Phase 1/2 · combination
10.6%100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
2%100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
25%
NCT04689737 · Phase 4 · registry result, not featured evidence
—DOR/ISL
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
4.3%DOR/ISL: Base Study Week 0 - Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
6.2%DOR/ISL: Base Study Week 48-Week 9
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
2.6%DOR/ISL: Base Study Week 96-Week 1
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
0%DOR/ISL: Open-Label Extension Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
1.5%DOR/ISL: Post-Treatment Follow-Up
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
6.4%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
5.3%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
2.1%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
0%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
2.7%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
4.8%Group 1: DOR/ISL Weeks 0-48
NCT04223778 · Phase 3 · registry result, not featured evidence
4%Group 1: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 1: Doravirine/Islatravir (DO
NCT04223778 · Phase 3 · registry result, not featured evidence
3.7%Group 2: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
—DOR/ISL + ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
0%DOR/ISL+ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
0%DOR/ISL: Treatment Naive Cohort
NCT04295772 · Phase 2 · registry result, not featured evidence
0%DOR/ISL: Treatment Naive Cohort Ex
NCT04295772 · Phase 2 · registry result, not featured evidence
2.7%DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
0%DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
10.2%100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
7.3%200 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
2.3%50 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
10%25 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
0%
NCT04900974 · Phase 1 · registry result, not featured evidence
—
NCT02715700 · Phase 1 · registry result, not featured evidence · combination
0%200 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
7.5%f
NCT00458393 · Phase 3
show 15 more results
0%Rectal Gel Lubricant + Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence · combination
0%Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence
20%
NCT01380080 · Phase 4 · registry result, not featured evidence
7.7%
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
—200/300 mg, Daily, by Mouth
NCT00960622 · Phase 4 · registry result, not featured evidence
0%Truvada
NCT00960622 · Phase 4 · registry result, not featured evidence
9.7%
NCT00323492 · Phase 4 · registry result, not featured evidence
11.7%100 mg
NCT02275780 · Phase 3 · registry result, not featured evidence
9.6%1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
18.6%
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
10%
NCT01195467 · Phase 3 · registry result, not featured evidence
3.2%
NCT00625404 · Phase 3 · registry result, not featured evidence
20.3%400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence
7.4%NVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
10.4%NoNVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
100 mge
diarrhoea 18.8%
upper respiratory tract infection 16.7%
headache 16.4%
NCT02275780 · Phase 3 · combination
show 33 more results
nasopharyngitis 13.7%
upper respiratory tract infection 7.2%
headache 6.2%
NCT02403674 · Phase 3 · HIV · phase 3
headache 15.9%
diarrhoea 13.7%
nasopharyngitis 13.7%
NCT02403674 · Phase 3 · HIV · phase 3
nasopharyngitis 9.7%
upper respiratory tract infection 7.1%
diarrhoea 6.3%
NCT02403674 · Phase 3 · HIV · phase 3
dizziness 38.2%
diarrhoea 15.9%
headache 15.4%
NCT02403674 · Phase 3 · HIV · phase 3
aspartate aminotransferase increased 22.2%
blood alkaline phosphatase increased 11.1%
blood glucose increased 11.1%
NCT03332095 · Phase 1/2
glomerular filtration rate decreased 55.6%
alanine aminotransferase increased 46.7%
blood creatinine increased 46.7%
NCT03332095 · Phase 1/2 · combination
100 mg
creatinine renal clearance decreased 10.6%
low density lipoprotein increased 6.4%
abdominal pain upper 2.1%
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
100 mg
creatinine renal clearance decreased 8.2%
aspartate aminotransferase increased 4.1%
alanine aminotransferase increased 2%
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
vomiting 25%
headache 12.5%
NCT04689737 · Phase 4 · registry result, not featured evidence
headache 8.1%
covid-19 5.9%
arthralgia 5%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
covid-19 13.1%
lymphocyte count decreased 10.5%
cd4 lymphocytes decreased 9.2%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
lymphocyte count decreased 32.3%
cd4 lymphocytes decreased 23.7%
covid-19 12.4%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
lymphocyte count decreased 15.9%
cd4 lymphocytes decreased 11.4%
covid-19 1.5%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
covid-19 2.6%
nasopharyngitis 2%
diarrhoea 1%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
100 mg/0.75 mg
covid-19 14.1%
headache 10.4%
lymphocyte count decreased 9.1%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
100 mg/0.75 mg
lymphocyte count decreased 24.1%
cd4 lymphocytes decreased 10.5%
covid-19 7.5%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
100 mg/0.75 mg
lymphocyte count decreased 17.1%
cd4 lymphocytes decreased 8.2%
upper respiratory tract infection 2.7%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
100 mg/0.75 mg
lymphocyte count decreased 14.3%
accidental overdose 0%
arthralgia 0%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
100 mg/0.75 mg
upper respiratory tract infection 6.3%
insomnia 1.8%
headache 0.9%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
headache 10.7%
accidental overdose 7.1%
covid-19 5.4%
NCT04223778 · Phase 3 · registry result, not featured evidence
lymphocyte count decreased 20.2%
cd4 lymphocytes decreased 14%
covid-19 13%
NCT04223778 · Phase 3 · registry result, not featured evidence
covid-19 17.5%
lymphocyte count decreased 13.5%
cd4 lymphocytes decreased 12%
NCT04223778 · Phase 3 · registry result, not featured evidence
blood creatine phosphokinase increased 28.6% (placebo 14.3%)
diarrhoea 28.6% (placebo 14.3%)
anaemia 14.3% (placebo 0%)
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
dizziness 33.3%
dyspepsia 33.3%
headache 33.3%
NCT04295772 · Phase 2 · registry result, not featured evidence
covid-19 100%
adjustment disorder 0%
back pain 0%
NCT04295772 · Phase 2 · registry result, not featured evidence
oropharyngeal pain 10.8%
cough 8.1%
nasal congestion 8.1%
NCT04295772 · Phase 2 · registry result, not featured evidence
cough 28.6%
oropharyngeal pain 21.4%
rhinorrhoea 21.4%
NCT04295772 · Phase 2 · registry result, not featured evidence
100 mg
nasopharyngitis 17.6%
diarrhea 14.8%
dizziness 14.8%
NCT01632345 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 29.3%
nausea 22%
headache 17.1%
NCT01632345 · Phase 2 · registry result, not featured evidence
50 mg
abnormal dreams 20.9%
nausea 16.3%
headache 14%
NCT01632345 · Phase 2 · registry result, not featured evidence
25 mg
diarrhea 25%
fatigue 17.5%
influenza 15%
NCT01632345 · Phase 2 · registry result, not featured evidence
200 mg
diarrhoea 33.3% (placebo 0%)
headache 33.3% (placebo 33.3%)
abdominal pain 16.7% (placebo 0%)
NCT01466985 · Phase 1 · registry result, not featured evidence
25 mg
alanine aminotransferase increased 16.7% (placebo 0%)
aspartate aminotransferase increased 16.7% (placebo 0%)
decreased appetite 16.7% (placebo 0%)
NCT01466985 · Phase 1 · registry result, not featured evidence
f
pharyngitis 20.2% (placebo 22.9%)
parasitic infection intestinal 18.8% (placebo 17.6%)
alanine aminotransferase increased 12.3% (placebo 12.6%)
NCT00458393 · Phase 3
show 13 more results
erectile dysfunction 4.8%
gastroenteritis 4.8%
headache 4.8%
NCT02401230 · Phase 4 · registry result, not featured evidence · combination
gastroenteritis 5.3%
pulmonary embolism 5.3%
anxiety 0%
NCT02401230 · Phase 4 · registry result, not featured evidence
neutrophil count decreased 38%
blood albumin decreased 35.6%
blood sodium decreased 34%
NCT01380080 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 9%
diarrhea 8.4%
cough 5.2%
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 9.7%
abdominal pain 4.2%
bronchitis 4.2%
NCT00323492 · Phase 4 · registry result, not featured evidence
100 mg
diarrhoea 18.8%
upper respiratory tract infection 16.7%
headache 16.4%
NCT02275780 · Phase 3 · registry result, not featured evidence
1200 mg QD + Truvada
headache 15.8%
nausea 13.6%
diarrhoea 13.4%
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 22.1%
jaundice 22.1%
ocular icterus 20.1%
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
bilateral arm pain 2.5%
cellulitis 2.5%
diarrhoea 2.5%
NCT01195467 · Phase 3 · registry result, not featured evidence
blood phosphorus decreased 19.4% (placebo 18.3%)
aspartate aminotransferase increased 13.1% (placebo 11.5%)
headache 13.1% (placebo 14.3%)
NCT00625404 · Phase 3 · registry result, not featured evidence
400 mg b.i.d.
nasopharyngitis 26.7%
headache 26%
diarrhoea 25.6%
NCT00369941 · Phase 3 · registry result, not featured evidence
cough 23.1%
neutrophil count decreased 23.1%
rash 23.1%
NCT00089505 · Phase 3 · registry result, not featured evidence
neutrophil count decreased 27.3%
rash 26.5%
cough 24.1%
NCT00089505 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cTrial phases differ: Phase 3 versus Phase 4.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. ePopulation comparability has not been reviewed for 24 of these studies.
  6. fPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Doravirine

CD4+ 198.4% (n=344) vs 188.4% (n=329) ATRIPLA @ 48wk
absolute change · percentage points
NCT02403674 · Phase 3 · HIV · phase 3
show 3 more results
237.7% (n=337) vs 223% (n=311) ATRIPLA @ 96wk
NCT02403674 · Phase 3 · HIV · phase 3
-0.7% (n=313) vs 8.7% (n=311) Baseline Antiretroviral Therapy (ART) @ 48wk
NCT04223778 · Phase 3 · registry result, not featured evidence
5.29% (n=289) vs 0.16% (n=285) Baseline Antiretroviral Therapy (ART) @ 96wk
NCT04223778 · Phase 3 · registry result, not featured evidence
LDL-C -1.58% (n=330) vs 8.74% (n=305) ATRIPLA @ 48wk
percent change · % of baseline
NCT02403674 · Phase 3 · HIV · phase 3
Non-HDL-C -3.83% (n=333) vs 13.26% (n=314) ATRIPLA @ 48wk
percent change · % of baseline
NCT02403674 · Phase 3 · HIV · phase 3
Total Cholesterol -1.97% (n=333) vs 21.77% (n=314) ATRIPLA @ 48wk
percent change · % of baseline
NCT02403674 · Phase 3 · HIV · phase 3
Triglycerides -12.4% (n=333) vs 22.01% (n=314) ATRIPLA @ 48wk
percent change · % of baseline
NCT02403674 · Phase 3 · HIV · phase 3
HDL-C 1.86% (n=333) vs 8.51% (n=314) ATRIPLA @ 48wk
percent change · % of baseline
NCT02403674 · Phase 3 · HIV · phase 3
HIV-1 RNA LT 200 Copies 97.7% (n=44) @ 24wk
responder rate · % of participants
No placebo or comparator arm
NCT03332095 · Phase 1/2 · combination
show 2 more results
97.7% (n=44) @ 48wk
NCT03332095 · Phase 1/2 · combination
92.9% (n=42) @ 96wk
NCT03332095 · Phase 1/2 · combination
HIV-1 RNA Less Than 50 Copies 97.7% (n=43) @ 24wk
responder rate · % of participants
No placebo or comparator arm
NCT03332095 · Phase 1/2 · combination
show 4 more results
97.6% (n=42) @ 48wk
NCT03332095 · Phase 1/2 · combination
92.5% (n=40) @ 96wk
NCT03332095 · Phase 1/2 · combination
94.1% (n=34) @ 24wk
NCT04295772 · Phase 2 · registry result, not featured evidence
100% (n=1) @ 24wk
NCT04295772 · Phase 2 · registry result, not featured evidence
HIV-1 RNA Less Than 40 Copies 97.7% (n=43) @ 24wk
responder rate · % of participants
No placebo or comparator arm
NCT03332095 · Phase 1/2 · combination
show 2 more results
97.6% (n=42) @ 48wk
NCT03332095 · Phase 1/2 · combination
92.5% (n=40) @ 96wk
NCT03332095 · Phase 1/2 · combination
HIV-1 RNA -2.6 log @ 24wk
absolute change · log
No placebo or comparator arm
NCT03332095 · Phase 1/2 · combination
show 2 more results
-2.1 log @ 48wk
NCT03332095 · Phase 1/2 · combination
-4.3 log @ 96wk
NCT03332095 · Phase 1/2 · combination
CD4+ 84.8 cells/uL @ 24wk
absolute change · cells/uL
No placebo or comparator arm
NCT03332095 · Phase 1/2 · combination
show 4 more results
80.1 cells/uL @ 48wk
NCT03332095 · Phase 1/2 · combination
42.5 cells/uL @ 96wk
NCT03332095 · Phase 1/2 · combination
-112.1 cells/uL @ 24wk
NCT04295772 · Phase 2 · registry result, not featured evidence
705 cells/uL @ 24wk
NCT04295772 · Phase 2 · registry result, not featured evidence
CD4 -1.5% (n=43) @ 24wk
percent change · % of baseline
No placebo or comparator arm
NCT03332095 · Phase 1/2 · combination
show 2 more results
-0.4% (n=43) @ 48wk
NCT03332095 · Phase 1/2 · combination
-0.5% (n=38) @ 96wk
NCT03332095 · Phase 1/2 · combination

+ 32 further endpoints in the CSV export.

Emtricitabine/tenofovir disoproxil fumarate

Cumulative Incidence of Death 4.8 vs 5.2 IPT Cumulative probability per 100 persons @ 24wk
absolute value · Cumulative probability per 100 persons
NCT01380080 · Phase 4 · registry result, not featured evidence
Cumulative Incidence of Disease Progression 16.6 vs 11.3 IPT Cumulative probability per 100 persons @ 96wk
absolute value · Cumulative probability per 100 persons
NCT01380080 · Phase 4 · registry result, not featured evidence
HIV Disease Progression 17.1 vs 12.5 IPT Cumulative probability per 100 persons @ 24wk
absolute value · Cumulative probability per 100 persons
NCT01380080 · Phase 4 · registry result, not featured evidence
show 1 more result
19.3 vs 15.3 IPT Cumulative probability per 100 persons @ 48wk
NCT01380080 · Phase 4 · registry result, not featured evidence
HIV-1 RNA Less Than 400 Copies 0% (n=424) vs 0.01% (n=426) IPT @ 0wk
event count · % of participants
NCT01380080 · Phase 4 · registry result, not featured evidence
show 3 more results
0.46% (n=424) vs 0.49% (n=426) IPT @ 4wk
NCT01380080 · Phase 4 · registry result, not featured evidence
0.84% (n=424) vs 0.85% (n=426) IPT @ 24wk
NCT01380080 · Phase 4 · registry result, not featured evidence
0.87% (n=424) vs 0.89% (n=426) IPT @ 48wk
NCT01380080 · Phase 4 · registry result, not featured evidence
CD4+ Cell 18 vs 19 IPT cells/uL @ 0wk
event count · cells/uL
NCT01380080 · Phase 4 · registry result, not featured evidence
show 3 more results
74 vs 76 IPT cells/uL @ 4wk
NCT01380080 · Phase 4 · registry result, not featured evidence
121 vs 121 IPT cells/uL @ 24wk
NCT01380080 · Phase 4 · registry result, not featured evidence
176 vs 172 IPT cells/uL @ 48wk
NCT01380080 · Phase 4 · registry result, not featured evidence
HIV-1 RNA LT 200 Copies 84.4% (n=154) vs 82.1% (n=156) ABC/3TC @ 48wk
responder rate · % of participants
Snapshot Responder Analysis (Virologic Success)
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
HIV-1 RNA Less Than 50 Copies 79.9% (n=154) vs 77.6% (n=156) ABC/3TC @ 48wk
responder rate · % of participants
Snapshot Responder Analysis (Virologic Success)
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
Peak VO2 Change mL/Min 2.2 vs 2.8 Combivir or Trizivir kg @ 24wk200/300 mg, Daily, by Mouth
absolute change · kg
NCT00960622 · Phase 4 · registry result, not featured evidence
HIV Incidence 3.2% (n=1024) vs 3.4% (n=1032) placebo @ 52wk
event rate · % of participants
NCT00625404 · Phase 3 · registry result, not featured evidence · converted to % from 33 participants as posted
HIV-1 RNA Less Than 400 Copies Per 86.1% (n=280) vs 81.9% (n=281) Efavirenz @ 48wk400 mg b.i.d.
event count · % of participants
NCT00369941 · Phase 3 · registry result, not featured evidence · converted to % from 241 Participants as posted
show 7 more results
90% (n=280) vs 85.8% (n=281) Efavirenz @ 48wk*400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence · converted to % from 252 Participants as posted
81.1% (n=281) vs 78.7% (n=282) Efavirenz @ 96wk*400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence · converted to % from 228 Participants as posted
85.4% (n=281) vs 81.2% (n=282) Efavirenz @ 96wk*400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence · converted to % from 240 Participants as posted
75.4% (n=281) vs 68.1% (n=282) Efavirenz @ 156wk*400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence · converted to % from 212 Participants as posted
79.7% (n=281) vs 72% (n=282) Efavirenz @ 156wk*400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence · converted to % from 224 Participants as posted
71% (n=279) vs 61.3% (n=279) Efavirenz @ 240wk*400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence · converted to % from 198 Participants as posted
73.8% (n=279) vs 64.9% (n=279) Efavirenz @ 240wk*400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence · converted to % from 206 Participants as posted
CD4 189.1 vs 163.3 Efavirenz count @ 48wk400 mg b.i.d.
absolute change · count
NCT00369941 · Phase 3 · registry result, not featured evidence
show 3 more results
239.6 vs 224.8 Efavirenz count @ 96wk400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence
331.7 vs 295.2 Efavirenz count @ 156wk400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence
373.7 vs 311.6 Efavirenz count @ 240wk400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence
Virologic Failure 23% (n=121) vs 4% (n=120) LPV/r @ 48wk
absolute value · percentage points
week 48 percent of virologic failure or death
NCT00089505 · Phase 3 · registry result, not featured evidence
show 1 more result
14% (n=249) vs 4% (n=120) LPV/r @ 48wk
week 48 percent of virologic failure or death
NCT00089505 · Phase 3 · registry result, not featured evidence

+ 3 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Doravirine's landscape · Emtricitabine/tenofovir disoproxil fumarate's landscape